Objective: To compare the safety and efficacy of atomoxetine, a selective inhibitor of the norepinephrine transporter, versus placebo in Attention-Deficit/Hyperactivity Disorder (ADHD) patients with comorbid Oppositional Defiant Disorder (ODD).
Methods: A subset analysis of 98 children from two identical, multi-site, double-blind, randomized, placebo-controlled trials involving 9 weeks of treatment with atomoxetine or placebo was conducted. Patients met DSM-IV ADHD criteria. ODD was diagnosed with the Diagnostic Interview for Children and Adolescents-IV (DICA-IV; Reich, Welner, & Herjanic, 1997). ADHD severity was assessed with the ADHD Rating Scale-IV-Parent Version: Investigator Administered and Scored (ADHD-RS-IV-Parent:Inv; DuPaul, Power, Anastopoulos, & Reid, 1998); the short version of the Conners’ Parent Rating Scales-Revised (CPRS-R:S; Conners, 2000); and the Clinical Global Impressions of ADHD Severity (CGI-ADHD-S; Guy, 1976). Clinical response was defined as a ≥ 25% reduction in ADHD-RS-IV-Parent:Inv total score.
Results: ADHD-RS-IV-Parent:Inv, CGI-ADHD-S, and three CPRS-R:S subscale scores improved markedly with atomoxetine treatment. However, a decrease in the CPRS-R:S Oppositional subscore for atomoxetine-treated patients was not significantly greater than scores for placebo-treated patients. Clinical response rates were 65.4% in the atomoxetine group, and 36.4% in the placebo group (p = .007).
Conclusion: Atomoxetine was effective for the treatment of ADHD in patients with comorbid ODD. It did not significantly reduce the severity of ODD symptoms, and was well tolerated by the patients.
Get full access to this article
View all access options for this article.
References
1.
American Academy of Pediatrics (2000). Clinical practice guideline: Diagnosis and evaluation of the child with Attention-Deficit/Hyperactivity Disorder. Pediatrics, 105, 1158-1170.
2.
American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th Ed. - Text Revision). Washington, DC: Author.
3.
August, G. J., Realmuto, G. M., Joyce, T., & Hektner, J. M. (1999). Persistence and desistance of Oppositional Defiant Disorder in a community sample of children with ADHD. Journal of the American Academy of Child Psychiatry, 38, 1262-1270.
4.
Bymaster, F. P., Katner, J., Nelson, D. L., Hemricke-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in Attention-Deficit/Hyperactivity Disorder. Neuropsychopharmacology, 27, 699-711.
5.
Comings, D. E., Gade-Andavolu, R., Gonzalez, N., Wu, S., Muhleman, D., Blake, H., et al. (2000). Multivariate analysis of associations of 42 genes in ADHD, ODD and conduct disorder. Clinical Genetics, 58, 31-40.
Dunne, J. E. (1999). Attention-Deficit/Hyperactivity Disorder and associated childhood disorders. Primary Care, 26, 349-372.
8.
DuPaul, G. J., Power, T. J., Anastopoulos, A. D., & Reid, R. (1998). ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York: Guilford Press.
9.
Goldman, L. S., Genel, M., Bezman, R. J., & Slanetz, P. J. (1998). Diagnosis and treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. Journal of the American Medical Association, 279, 1100-1107.
10.
Guy, W. (1976). ECDEU Assessment Manual for Psychopharmacology, Revised. Bethesda, MD: United States Department of Health, Education, and Welfare.
11.
Kaufman, J., Birmaher, B., Brent, D., Rao, U., & Ryan, N. (1996). Kiddie-SADS-Present and Lifetime Version (K-SADS-PL): The Department of Psychiatry, University of Pittsburgh School of Medicine.
12.
Klein, R. G., Abikoff, H., Klass, E., Ganaeles, D., Seese, L. M., & Pollack, S. (1997). Clinical efficacy of methylphenidate in conduct disorder with and without Attention Deficit Hyperactivity Disorder. Archives of General Psychiatry, 54, 1073-1080.
13.
Kratochvil, C. (2003, May). A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. Paper presented at the Annual Meeting of the American Psychiatric Association, San Francisco, CA.
14.
Kuhne, M., Schachar, R., & Tannock, R. (1997). Impact of comorbid oppositional or conduct problems on Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36, 1715-1725.
15.
Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C., et al. (2002). Once-daily atomoxetine treatment for children and adolescents with Attention-Deficit/Hyperactivity Disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
16.
Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., et al. (2001). Atomoxetine in the treatment of children and adolescents with Attention-Deficit/Hyperactivity Disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, e83.
17.
MTA Cooperative Group (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Group. Multimodal Treatment Study of Children with ADHD, Archives of General Psychiatry, 56, 1073-1086.
18.
Newcorn, J. H., Halperin, J. M., Jensen, P. S., Abikoff, H. B., Arnold, L. E., Cantwell, D. P., et al. (2001). Symptom profiles in children with ADHD: Effects of comorbidity and gender. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 137-146.
19.
Popper, C. W. (2000). Pharmacological alternatives to psychostimulants for the treatment of Attention-Deficit/Hyperactivity Disorder. Child and Adolescent Psychiatric Clinics of North America, 9, 605-646.
20.
Reich, W., Welner, Z, & Herjanic, B. (1997). Diagnostic Interview for Children and Adolescents -IV (DICA-IV). Toronto, Canada: Multi-Health Systems.
21.
Spencer, T., Biederman, J., Heiligenstein, J., Wilens, T., Faries, D., Prince, J., et al. (2001). An open-label, dose-ranging study of atomoxetine in children with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 11, 251-265.
22.
Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., et al. (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
23.
Wechsler, D. (1991). Wechsler Intelligence Scale for Children (WISC-III). San Antonio, TX: The Psychological Corporation.
24.
World Medical Association (2002). Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Retrieved September 15, 2004 from http://www.wma.net/e/policy/pdf/17c.pdf.
